The past couple of years have been challenging for the company. But this could be the beginning of a new chapter.

Powerful new weight-loss medications are in the works to treat obesity. Doctors explain why more options are needed and the ...

Danish drugmaker Novo Nordisk's oral Wegovy (semaglutide) has recorded impressive early sales in the USA, and investors have ...

Eli Lilly is tackling a high-growth market: weight loss. The company’s weight loss portfolio brought in $10 billion in the ...

Novo Nordisk and Eli Lilly have dominated the market until now, but this year is set to bring oral drugs, generics, and a ...

Tonight’s digest tracks the accelerating use of trade and tariffs as geopolitical leverage, from Trump’s renewed pressure campaign over Greenland to Canada’s landmark trade reset with China. In the ...

True, Novo Nordisk is making progress in this field. It recently earned approval for an oral formulation of Wegovy, which ...

Novo Nordisk shares have surged on the back of its groundbreaking oral Wegovy approval, making it the first company to bring ...

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in active PsA and obesity.

Novo Nordisk (NYSE: NVO) was once the top player in the weight loss drug market. The company's medicine, Wegovy, practically ...

The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...